Showing 1,559 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Hepatitis C treatment

Will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?

Editor's pick
Hepatitis C New Drugs
10 December 2014
New & experimental HIV treatments

European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Editor's pick
Janssen
25 November 2014
Access to healthcare

Zimbabwe: Stealing Lives

Editor's pick
Al Jazeera (video)
24 November 2014
New & experimental hepatitis C treatment

CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Editor's pick
AbbVie press release
21 November 2014
Pharmaceutical industry

Pharmaceutical Industry Doing More to Improve Access to Medicine in Developing Countries; Performance on Some Aspects Lags

Editor's pick
Access to Medicine Index
18 November 2014
New & experimental HIV treatments

HIV Drug Development Pipeline Update, Fall 2014 Edition

Editor's pick
The Body Pro
17 November 2014
New & experimental hepatitis C treatment

Merck’s four-week treatment for hepatitis C misses the mark

Editor's pick
Wall Street Journal
11 November 2014
Pharmaceutical industry

HIV generics in the U.S.: Sooner or later?

Editor's pick
The Body
10 November 2014
New & experimental HIV treatments

Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

Editor's pick
BioPharma Dive
7 November 2014
Pharmaceutical industry

Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

Editor's pick
Wall Street Journal
5 November 2014
Generic medicines

Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds

News
4 November 2014
HIV treatment

How Will Generic Drugs Affect HIV Treatment in the U.S.?

Editor's pick
The Body
31 October 2014
Pharmaceutical industry

GSK eyes prime FTSE 100 slot for standalone HIV drugs business

Editor's pick
Reuters
26 October 2014
Pharmaceutical industry

GlaxoSmithKline weighs an IPO for HIV-focused ViiV as it sharpens the budget axe

Editor's pick
FierceBiotech
22 October 2014
Pharmaceutical industry

Juncker seen making U-turn on medicines policy

Editor's pick
EurActiv
17 October 2014
Hepatitis C treatment

Unique 'pay if you clear' proposal for new hepatitis drug

Editor's pick
BBC
15 October 2014
New & experimental hepatitis C treatment

Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

Editor's pick
Fair Pricing Coalition
15 October 2014
Pharmaceutical industry

If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Editor's pick
Wall Street Journal
15 October 2014
New & experimental hepatitis C treatment

In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug

Editor's pick
Fierce Biotech
7 October 2014
Pharmaceutical industry

Europe: Pharma industry denies it lobbied for medicines to move to DG Enterprise

Editor's pick
EurActiv
1 October 2014
Pharmaceutical industry

J&J makes a splash in hep C with a $1.75B deal for Alios

Editor's pick
Fierce Biotech
1 October 2014
New & experimental HIV treatments

Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

Editor's pick
Gilead press release
25 September 2014
New & experimental HIV treatments

Gilead Sciences: A Preview of Important HIV Drug Study Results

Editor's pick
The Street
23 September 2014
Health services & systems

US: How Insurers Are Finding Ways to Shift Costs to the Sick

Editor's pick
New York Times
18 September 2014